Human Chorionic Gonadotropin (HCG) dosing & administration

Lee JA, Ramasamy R · 2018

This review established that HCG therapy can help re-establish or maintain spermatogenesis in hypogonadal men, making it an essential tool for fertility preservation during testosterone therapy. It highlighted HCG's role in maintaining intratesticular testosterone levels.

Ramasamy R, Armstrong JM, Lipshultz LI · 2015

This study showed that HCG can reverse azoospermia caused by testosterone therapy and maintain elevated intratesticular testosterone levels. The research demonstrated that combining HCG with selective estrogen receptor modulators effectively maintains spermatogenesis in hypogonadal men.

Boeri L, Capogrosso P, Salonia A · 2021

This comprehensive review found that combined HCG and FSH therapy promotes testicular growth in almost all patients, spermatogenesis in approximately 80%, and pregnancy rates around 50% in men with hypogonadotropic hypogonadism. Treatment duration of 12-24 months was typical for optimal results.

Cho MC, Lee H, Kim SW · 2025

This study demonstrated that gonadotropin therapy with HCG and FSH successfully induced spermatogenesis in 82% of patients with prepubertal-onset hypogonadotropic hypogonadism. Larger baseline testicular volume was the best predictor of treatment success.

Clift AK, Johnson H, Huang DR, Morgentaler A · 2026

In a study of over 9,500 men, 75% received HCG as part of their testosterone therapy protocol. The combination showed a favorable safety profile with significant improvements in quality of life, sexual function, energy levels, and performance in work and sport.

Organon (FDA label / DailyMed) · 2023

FDA-labeled intramuscular regimens for male hypogonadotropic hypogonadism (500-1,000 IU 3x/week x3 wk then 2x/week x3 wk) and for inducing spermatogenesis (4,000 IU 3x/week x6-9 mo, then 2,000 IU 3x/week x3 mo).

Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, et al. · 2005

Twenty-nine men with normal reproductive function received 200 mg testosterone enanthate weekly plus saline or 125, 250, or 500 IU hCG every other day for three weeks. Intratesticular testosterone fell 25% below baseline at 125 IU, held within 7% of baseline at 250 IU, and rose 26% above baseline at 500 IU — establishing the every-other-day low-dose range that maintains testicular testosterone during exogenous testosterone use.

Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI · 2013

Men on testosterone replacement who co-administered 500 IU hCG every other day maintained semen parameters over more than one year of follow-up, with no cases of azoospermia — against the roughly 40% azoospermia rate reported with testosterone therapy alone.

Smit DL, Verdegaal T, Bond P · 2025

Nineteen men at a Dutch harm-reduction clinic who continued non-prescribed androgen use were treated with hCG; mean total sperm count rose from 18.0 to 146.9 million and total motile sperm count from 1.1 to 66.9 million. A minority remained oligospermic or azoospermic.

Lunenfeld B · 2004

Gonadotrophin extracts prepared from human placenta and urine began to be used in the management of infertility in the early 1930s, with pregnancies reported following their use in the late 1930s — placing clinical use of chorionic gonadotrophin preparations at more than eight decades.

Smitz J, Platteau P · 2020

The hCG beta subunit differs from LH by a carboxy-terminal peptide (CTP) extension carrying four O-linked carbohydrate chains; terminal sialic acid content drives charge heterogeneity. The CTP extension confers hCG a markedly increased half-life versus LH (approximately 24-34 h vs approximately 30-60 min) and a markedly longer dissociation rate from the LH/CG receptor. Receptor activation signals through adenylyl cyclase and the cAMP/protein kinase A pathway, producing steroidogenesis.

Zirkin BR, Papadopoulos V · 2018

In the adult testis, luteinizing hormone binding to Leydig cell LH receptors stimulates cAMP production, increasing cholesterol translocation into the mitochondria. Steroidogenic acute regulatory protein (StAR) acts at the mitochondrial contact-site complex to enhance cholesterol movement across the membranes; cholesterol is then metabolised to pregnenolone by CYP11A1 and on to testosterone by mitochondrial and smooth endoplasmic reticulum enzymes.

Prior M, Stewart J, McEleny K, Dwyer AA, Quinton R · 2018

hCG acts as a long-acting LH analogue stimulating spermatogenesis. Previously virilised men with adult-onset hypogonadotropic hypogonadism and normal testicular volume respond well to hCG monotherapy; men with congenital hypogonadotropic hypogonadism require combined hCG plus FSH.

Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, et al. · 2009

Thirty-six men with severe hypogonadotropic hypogonadism received 1,000 U hCG on alternate days for 3-6 months followed by hCG plus follitropin alfa. Testis volumes increased during treatment. Acne occurred in 52% of patients and was the most common side effect; gynecomastia was reported in 10%.

Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED · 2014

Symptomatic hypogonadism, testicular atrophy and gynecomastia are consequences of non-prescribed anabolic-androgenic steroid use. Management strategies for anabolic steroid-associated hypogonadism include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators.

Rainer Q, Pai R, Zucker I, Ramasamy R, Masterson TA · 2022

Twenty-eight men with previous exogenous testosterone use were switched to hCG monotherapy and followed with laboratory testing of testosterone, LH, FSH, estradiol, hematocrit, HbA1c and PSA. Hematocrit fell significantly (45.27% to 44.16%) and no thromboembolic events were reported; testosterone rose in men whose baseline was drawn outside the prior therapeutic window.

Madhusoodanan V, Patel P, Lima TFN, Gondokusumo J, Lo E, Thirumavalavan N, Lipshultz LI, Ramasamy R · 2019

In 20 men treated with hCG monotherapy for hypogonadal symptoms, mean testosterone rose 49.9% from 362 ng/dL to 519.8 ng/dL over a median 8 months, with 50% reporting symptom improvement and no adverse events.

Mulhall JP, Trost LW, Brannigan RE, et al. (American Urological Association) · 2018

Statement 27: clinicians may use aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or a combination thereof in men with testosterone deficiency desiring to maintain fertility. Hemoglobin and hematocrit are measured before therapy and monitored on treatment; PSA is measured in men over 40 before starting; testosterone levels are measured at follow-up and every 6-12 months on therapy.

Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G · 1995

Meta-analysis of eight controlled and 16 uncontrolled trials of HCG as adjunctive obesity therapy. Of the 12 studies scoring 50 or more on methodological quality, one reported HCG a useful adjunct. The authors concluded there is no scientific evidence that HCG is effective in the treatment of obesity: it does not bring about weight loss or fat redistribution, nor reduce hunger.

U.S. Food and Drug Administration · 2020

FDA consumer update advising consumers to avoid HCG weight-loss products: "any loss is from severe calorie restriction. Not from the HCG," and "Living on 500 calories a day is not only unhealthy but also dangerous." All drug products claiming to contain homeopathic HCG are illegally marketed; there are no FDA-approved HCG products for weight loss.

Amann RP · 2008

Review of human spermatogenic kinetics. Heller and Clermont (1963, 1964) concluded that one cycle of the seminiferous epithelium requires approximately 16 days and that the duration of spermatogenesis is approximately 74 days — the value that remains the accepted figure.

Muir CA, Zhang T, Jayadev V, Conway AJ, Handelsman DJ · 2024

Meta-analysis of 41 studies and 1,673 men. Sperm appeared in the ejaculate in 78% of treated men after a median 18 months. Treatment-related increases in testosterone and testicular volume did not differ between hCG monotherapy and combined hCG/FSH, although combined therapy was more efficacious for inducing spermatogenesis.